Biosimilars could get Brexit boost from MHRA plans

Developers of biosimilar medicines could find it easier to gain a licence to market their products in the UK from next year under plans put forward by a UK authority to partly diverge from EU regulations after the Brexit transition period expires.

Read Complete Article

MITLA is a member of the INPLP

    Subscribe for the latest
    IT Law updates

    Receive the latest IT Law updates straight to your inbox, gain access to our exclusive industry events, keep up to date with MITLA.